MX2015012873A - Reticuladores quimicos. - Google Patents
Reticuladores quimicos.Info
- Publication number
- MX2015012873A MX2015012873A MX2015012873A MX2015012873A MX2015012873A MX 2015012873 A MX2015012873 A MX 2015012873A MX 2015012873 A MX2015012873 A MX 2015012873A MX 2015012873 A MX2015012873 A MX 2015012873A MX 2015012873 A MX2015012873 A MX 2015012873A
- Authority
- MX
- Mexico
- Prior art keywords
- lysosomal
- contacting
- targeting peptide
- crosslinking agent
- introduce
- Prior art date
Links
- 239000000126 substance Substances 0.000 title abstract 2
- 239000004971 Cross linker Substances 0.000 title 1
- 230000002132 lysosomal effect Effects 0.000 abstract 5
- 230000008685 targeting Effects 0.000 abstract 3
- 102000004190 Enzymes Human genes 0.000 abstract 2
- 108090000790 Enzymes Proteins 0.000 abstract 2
- 125000000729 N-terminal amino-acid group Chemical group 0.000 abstract 2
- 125000003172 aldehyde group Chemical group 0.000 abstract 2
- 239000003431 cross linking reagent Substances 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 230000021615 conjugation Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000863 peptide conjugate Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/18—Carboxylic ester hydrolases (3.1.1)
- C12N9/20—Triglyceride splitting, e.g. by means of lipase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2405—Glucanases
- C12N9/2408—Glucanases acting on alpha -1,4-glucosidic bonds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2405—Glucanases
- C12N9/2434—Glucanases acting on beta-1,4-glucosidic bonds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2465—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase (3.2.1.22)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2477—Hemicellulases not provided in a preceding group
- C12N9/2488—Mannanases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/0102—Alpha-glucosidase (3.2.1.20)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicinal Preparation (AREA)
Abstract
Se divulgan en la presente métodos de conjugación química que comprenden poner en contacto una enzima lisosomal con un primer agente de reticulación para introducir grupos aldehído; poner en contacto un péptido de direccionamiento lisosomal con un segundo agente de reticulación para introducir un grupo hidrazida en el residuo terminal N; poner en contacto la enzima lisosomal con grupos aldehído del paso a. con el péptido de direccionamiento lisosomal con un grupo hidrazida en el residuo terminal N del paso b; y formar un conjugado de enzima lisosomal-péptido de direccionamiento lisosomal.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361794784P | 2013-03-15 | 2013-03-15 | |
PCT/US2014/027818 WO2014143734A2 (en) | 2013-03-15 | 2014-03-14 | Chemical crosslinkers |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2015012873A true MX2015012873A (es) | 2016-02-03 |
Family
ID=51537517
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2015012873A MX2015012873A (es) | 2013-03-15 | 2014-03-14 | Reticuladores quimicos. |
Country Status (15)
Country | Link |
---|---|
US (2) | US9889203B2 (es) |
EP (2) | EP2976092B1 (es) |
JP (2) | JP6506250B2 (es) |
KR (1) | KR20150132126A (es) |
CN (1) | CN105189742A (es) |
AU (2) | AU2014228231B2 (es) |
BR (1) | BR112015022780A2 (es) |
CA (1) | CA2902210C (es) |
ES (1) | ES2804594T3 (es) |
HK (1) | HK1215049A1 (es) |
IL (1) | IL240209A0 (es) |
MX (1) | MX2015012873A (es) |
SG (1) | SG11201505936QA (es) |
WO (2) | WO2014143734A2 (es) |
ZA (1) | ZA201506363B (es) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2804594T3 (es) * | 2013-03-15 | 2021-02-08 | Amicus Therapeutics Inc | Reticuladores químicos |
GB201508025D0 (en) | 2015-05-11 | 2015-06-24 | Ucl Business Plc | Fabry disease gene therapy |
KR101847536B1 (ko) * | 2015-06-02 | 2018-04-11 | 한국생명공학연구원 | 효모 세포벽 만노단백질 유래의 당사슬을 이용한 만노스-6-인산 당사슬이 부가된 당단백질의 제조방법 |
SG11202010533WA (en) * | 2018-04-30 | 2020-11-27 | Amicus Therapeutics Inc | Gene therapy constructs and methods of use |
CN113631182A (zh) | 2018-10-10 | 2021-11-09 | 阿米库斯治疗学公司 | 二硫键稳定的多肽组合物和使用方法 |
CA3154189A1 (en) * | 2019-10-10 | 2021-04-15 | Hung Do | Variant igf2 constructs |
AR124216A1 (es) | 2020-12-01 | 2023-03-01 | Univ Pennsylvania | Composiciones nuevas con motivos selectivos específicos del tejido y composiciones que las contienen |
EP4334334A1 (en) | 2021-04-23 | 2024-03-13 | The Trustees of The University of Pennsylvania | Novel compositions with brain-specific targeting motifs and compositions containing same |
WO2024130070A2 (en) | 2022-12-17 | 2024-06-20 | The Trustees Of The University Of Pennsylvania | Recombinant aav capsids with cardiac- and skeletal muscle- specific targeting motifs and uses thereof |
WO2024130067A2 (en) | 2022-12-17 | 2024-06-20 | The Trustees Of The University Of Pennsylvania | Recombinant aav mutant vectors with cardiac and skeletal muscle-specific targeting motifs and compositions containing same |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5401650A (en) * | 1990-10-24 | 1995-03-28 | The Mount Sinai School Of Medicine Of The City University Of New York | Cloning and expression of biologically active α-galactosidase A |
CA2723664A1 (en) * | 2000-03-22 | 2001-09-27 | Solulink, Incorporated | Hydrazine-based and carbonyl-based bifunctional crosslinking reagents |
JP5137814B2 (ja) * | 2005-04-06 | 2013-02-06 | ジェンザイム・コーポレーション | 治療ターゲティングのための酸不安定リンカーを介するpegおよびポリシアルリソソーム酵素のコンジュゲート |
EP1877101B1 (en) * | 2005-04-28 | 2016-11-16 | Ventana Medical Systems, Inc. | Enzymes conjugated to antibodies via a peg heterobifuctional linker |
EP2046375B1 (en) * | 2006-07-20 | 2017-04-05 | The General Hospital Corporation | Methods and compositions for the selective activation of protoxins through combinatorial targeting |
WO2011041897A1 (en) * | 2009-10-06 | 2011-04-14 | Angiochem Inc. | Compositions and methods for the transport of therapeutic agents |
DK2714752T3 (en) * | 2011-05-27 | 2018-02-26 | Amicus Therapeutics Inc | PROCEDURES FOR THE CONNECTION OF TARGETING PEPTIDES TO RECOMBINANT LYSOSOMAL ENZYMES FOR IMPROVED TREATMENT OF LYSOSOMAL DISPOSAL DISEASES |
RU2014126484A (ru) * | 2011-12-01 | 2016-02-10 | Ангиочем Инк. | Нацеленные соединения лизосомальных ферментов |
ES2804594T3 (es) * | 2013-03-15 | 2021-02-08 | Amicus Therapeutics Inc | Reticuladores químicos |
-
2014
- 2014-03-14 ES ES14764160T patent/ES2804594T3/es active Active
- 2014-03-14 BR BR112015022780A patent/BR112015022780A2/pt not_active Application Discontinuation
- 2014-03-14 WO PCT/US2014/027818 patent/WO2014143734A2/en active Application Filing
- 2014-03-14 EP EP14764160.9A patent/EP2976092B1/en active Active
- 2014-03-14 JP JP2016502634A patent/JP6506250B2/ja active Active
- 2014-03-14 US US14/762,647 patent/US9889203B2/en active Active
- 2014-03-14 CA CA2902210A patent/CA2902210C/en active Active
- 2014-03-14 AU AU2014228231A patent/AU2014228231B2/en active Active
- 2014-03-14 WO PCT/US2014/027771 patent/WO2014143701A1/en active Application Filing
- 2014-03-14 MX MX2015012873A patent/MX2015012873A/es unknown
- 2014-03-14 CN CN201480008669.3A patent/CN105189742A/zh active Pending
- 2014-03-14 SG SG11201505936QA patent/SG11201505936QA/en unknown
- 2014-03-14 EP EP20170446.7A patent/EP3714893A1/en not_active Withdrawn
- 2014-03-14 KR KR1020157023763A patent/KR20150132126A/ko not_active Application Discontinuation
-
2015
- 2015-07-29 IL IL240209A patent/IL240209A0/en unknown
- 2015-08-31 ZA ZA2015/06363A patent/ZA201506363B/en unknown
-
2016
- 2016-03-15 HK HK16102953.3A patent/HK1215049A1/zh unknown
-
2018
- 2018-02-08 US US15/891,397 patent/US10814008B2/en active Active
-
2019
- 2019-03-28 JP JP2019063679A patent/JP2019142889A/ja active Pending
- 2019-05-16 AU AU2019203437A patent/AU2019203437A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20180185503A1 (en) | 2018-07-05 |
US9889203B2 (en) | 2018-02-13 |
IL240209A0 (en) | 2015-09-24 |
US10814008B2 (en) | 2020-10-27 |
EP2976092A2 (en) | 2016-01-27 |
CA2902210C (en) | 2021-07-20 |
WO2014143701A1 (en) | 2014-09-18 |
JP6506250B2 (ja) | 2019-04-24 |
AU2014228231A1 (en) | 2015-08-13 |
HK1215049A1 (zh) | 2016-08-12 |
SG11201505936QA (en) | 2015-09-29 |
JP2019142889A (ja) | 2019-08-29 |
EP2976092B1 (en) | 2020-04-22 |
BR112015022780A2 (pt) | 2018-02-06 |
EP2976092A4 (en) | 2016-11-23 |
AU2014228231B2 (en) | 2019-02-21 |
CA2902210A1 (en) | 2014-09-18 |
WO2014143734A3 (en) | 2014-12-04 |
AU2019203437A1 (en) | 2019-06-13 |
CN105189742A (zh) | 2015-12-23 |
US20160129126A1 (en) | 2016-05-12 |
WO2014143734A2 (en) | 2014-09-18 |
ES2804594T3 (es) | 2021-02-08 |
ZA201506363B (en) | 2017-11-29 |
EP3714893A1 (en) | 2020-09-30 |
KR20150132126A (ko) | 2015-11-25 |
JP2016515510A (ja) | 2016-05-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2015012873A (es) | Reticuladores quimicos. | |
EA201891277A1 (ru) | Композиции и способы интернализации ферментов | |
ZA202000027B (en) | Constructs specifically recognizing glypican 3 and uses thereof | |
MX2022014125A (es) | Anticuerpos y conjugados de los mismos. | |
MY186708A (en) | Constructs targeting afp peptide/mhc complexes and uses thereof | |
MX2016001317A (es) | Variantes de enzimas. | |
PH12017500785A1 (en) | INTERFERON a2B VARIANTS | |
SG10201810087QA (en) | Modified t lymphocytes having improved specificity | |
CO2018008427A2 (es) | Conjugado de enzimas terapéuticas | |
MX2017014056A (es) | Construcciones dirigidas a complejos de peptido e7 del subtipo 16 del virus de papiloma humano (hpv16-e7)/complejo principal de histocompatibilidad (mhc) y sus usos. | |
MX2016008448A (es) | Conjugados de var2csa-farmaco. | |
GB2519697A (en) | Golf fitting systems and related methods | |
MX2018010491A (es) | Proceso para la preparacion de un conjugado anticuerpo-rifamicina. | |
UY34335A (es) | ?dispositivos, sistemas, y métodos para procesar materiales heterogéneos?. | |
WO2012162494A3 (en) | Apparatus and methods including a bipolar junction transistor coupled to a string of memory cells | |
PH12018500159A1 (en) | Constructs targeting psa peptide/mhc complexes and uses thereof | |
IL272931A (en) | Peptide conjugates, conjugation process and their uses | |
MX2018010196A (es) | Proteinas de fusion de enzimas lisosomales terapeuticas dirigidas, formulaciones asociadas y usos de las mismas. | |
WO2015095240A3 (en) | Biosynthesis of 1-undecence and related terminal olefins | |
MX2020012057A (es) | Acido nucleico para el tratamiento de alergia por acaros. | |
TW201614071A (en) | Aptamer specific to colorectal cancer stem cell and application thereof | |
MX2016010719A (es) | Ensayos de aclaramiento de sustratos para enzimas lisosomales. | |
NZ733839A (en) | Amino acid and peptide conjugates and conjugation process | |
MY189268A (en) | Targeted/immunomodulatory fusion proteins and methods for making same | |
MY173515A (en) | Targeted/immunomodulatory fusion proteins and methods for making same |